The shares of Anavex Life Sciences ( NASDAQ: AVXL ) gained Thursday pre-market after the clinical-stage biotech announced better than expected patient enrollment in its EXCELLENCE Phase 2/3 study for Rett syndrome candidate ANAVEX®2-73 (blarcamesine).
With its enrollment at 92, exceeding the original target, Anavex ( AVXL ) expects to announce topline results from the EXCELLENCE trial in H2 2023.
The company had designed the multicenter, double-blind study to test the safety, tolerability, and efficacy of daily oral ANAVEX®2-73 or placebo in patients aged ? 5 years to 17.
Rett syndrome is a rare and genetically driven neurodevelopmental disorder that almost exclusively affects girls as the condition, with a prevalence rate of about one in 10K – 15K live female births, has no FDA-approved therapies.
“We are excited to complete enrollment in this multicenter study with ANAVEX®2-73 in Rett syndrome and look forward to reporting the results later this year.” Christopher Missling, Chief Executive of Anavex ( AVXL ), said.
Seeking Alpha contributor The Political Economist thinks that blarcamesine is “more effective, cheaper and safer than Leqembi,” an Alzheimer’s therapy for which developers Biogen ( BIIB ) and Eisai (( OTCPK:ESALY ) ( OTCPK:ESALF ) won the FDA nod in January.
For further details see:
Anavex gains as trial for Rett syndrome candidate exceeds enrollment target